ImmixBio's Lead Candidate Shows Improved Survival Over FDA-Approved Soft Tissue Cancer Drug

Immix Biopharma Inc IMMX announced positive interim data from an animal study in Soft Tissue Sarcoma (STS).
STS is a broad term for cancers that start in soft tissues (muscle, tendons, fat, lymph and blood vessels, and nerves).
After one treatment cycle, ImmixBio's lead candidate IMX-110 produced 75% survival vs. 0% survival for trabectedin in a connective tissue cancer Soft Tissue Sarcoma (STS) mice study.
Trabectedin is sold as Yondelis by Janssen, a Johnson & Johnson JNJ company.
Also Read: Immix Biopharma's IMX-110 / Anti-PD-1 Combo Therapy Shows Extended Median Survival In Animal Studies.
IMX-110 was compared against approved drugs used to treat STS in this study.
According to Meco et al., 2003 (trabectedin monotherapy treatment arm), trabectedin was dosed, and IMX-110 was administered at 2.0 mg/kg.
"We are excited to see continued evidence of IMX-110 anti-tumor activity versus approved therapies," said Ilya Rachman, CEO of ImmixBio. "We believe this is a preview of anti-tumor activity to be demonstrated in our two clinical trials to be kicked off in 2022: IMX-110 monotherapy and IMX-110 in combination with anti-PD-1 tislelizumab."
Price Action: IMMX shares are up 57.7% at $2.57 during the market session on the last check Friday.